Private equity is thriving in gastroenterology, with several equity-backed management groups taking over the market, Becker’s reports.
The number of private equity gastrointestinal groups grew by 28 percent, to 68, in 2021, according to a report jointly published by consulting firm Fraser Healthcare and pharma research firm Spherix Global Insights.
The influx of investment, however, is controversial, and many gastroenterologists warn against the cons of a private equity investment. Read more.
